Arrowhead Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Arrowhead Pharmaceuticals generated cash of -$462,851,000, which is less than the previous year. Cash used in financing activities reached the amount of $870,520,000 last year. Net change in cash is therefore -$8,206,000.
Cash Flow
| 2015 | -65.70M | 14.12M | 290.52K |
|---|---|---|---|
| 2016 | -64.42M | 13.44M | 55.13M |
| 2017 | -23.93M | -48.64M | 12.05M |
| 2018 | -47.22M | -7.43M | 59.95M |
| 2019 | 173.03M | -47.74M | 66.38M |
| 2020 | -95.39M | -240.77M | 257.94M |
| 2021 | 171.22M | -141.67M | 11.30M |
| 2022 | -136.13M | -5.41M | 65.18M |
| 2023 | -153.89M | -96.15M | 253.05M |
| 2024 | -462.85M | -420.07M | 870.52M |
ARWR Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 110.89M | 108.00M | 184.43M | 143.58M | 221.80M | 30.13M | 24.83M | 85.36M | 81.21M | 132.51M |
Operating activities | ||||||||||
Net income | -609.69M | -209.27M | -176.49M | -140.84M | -84.55M | 67.97M | -54.45M | -34.38M | -81.72M | -91.94M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 18.59M | 12.49M | 10.42M | 8.26M | 5.94M | 4.43M | 4.69M | 4.69M | 3.26M | 2.33M |
Stock-based compensation expense | 73.96M | 78.13M | 120.89M | 76.67M | 43.38M | 12.39M | 0 | 7.89M | 11.59M | 10.23M |
| Deferred income tax benefit | 73.96M | 78.13M | 120.89M | 76.67M | 43.38M | 12.39M | 0 | 7.89M | 11.59M | 10.23M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 1.41M | 8.84M | -9.40M | -184.31K | -333.98K | -259.57K | 7.20K | -75K | 0 |
Inventories | 0 | 0 | 0 | 9.16M | 1.60M | -1.26M | 1.33M | 2.41M | -1.89M | 0 |
Accounts payable | -5.53M | 32.99M | -6.58M | 2.62M | -821.01K | 4.84M | -1.27M | -3.50M | 2.55M | 2.49M |
Cash generated by operating activities | -462.85M | -153.89M | -136.13M | 171.22M | -95.39M | 173.03M | -47.22M | -23.93M | -64.42M | -65.70M |
Investing activities | ||||||||||
Purchases Of Investments | -720.94M | -246.14M | -223.39M | -240.70M | -278.96M | -90.26M | -52.08M | -44.97M | 0 | 0 |
Investments In Property Plant And Equipment | -141.46M | -176.73M | -52.77M | -23.56M | -11.95M | -12.00M | -1.42M | -7.91M | -3.86M | -1.97M |
Acquisitions Net | 0 | -80.58M | -47.36M | 141.67M | 240.77B | 47.74B | 7.43B | 0 | 0 | -10M |
Cash generated by investing activities | -420.07M | -96.15M | -5.41M | -141.67M | -240.77M | -47.74M | -7.43M | -48.64M | 13.44M | 14.12M |
Financing activities | ||||||||||
Common Stock Issued | 429.26M | 3.05M | 5.18M | 11.30M | 250.47M | 60.52M | 0 | 12.41M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | -54.66K | 0 | -634.18K | 0 |
Repayments of term debt | 392M | 0 | 0 | 0 | 0 | -2.41M | -208.50K | -197.79K | -217.54K | -213.99K |
Cash used in financing activities | 870.52M | 253.05M | 65.18M | 11.30M | 257.94M | 66.38M | 59.95M | 12.05M | 55.13M | 290.52K |
Net Change In Cash | -8.20M | 2.88M | -76.42M | 40.85M | -78.22M | 191.67M | 5.29M | -60.52M | 4.15M | -51.29M |
Cash at end of period | 102.68M | 110.89M | 108.00M | 184.43M | 143.58M | 221.80M | 30.13M | 24.83M | 85.36M | 81.21M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |